BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has reported encouraging results from a minipig Dose Range Finding (DRF) study for Probudur, its long-acting liposomal bupivacaine injection. Designed to provide immediate and extended pain relief at wound sites, Probudur aims to address unmet needs in post-surgical pain management.
The study evaluated the tolerance of Probudur in an incisional wound healing model using local injections around incision areas. All test subjects demonstrated favorable tolerance to the drug, with no adverse effects observed. These findings support the company’s ongoing development program and reinforce the potential of Probudur to deliver both immediate and sustained pain relief.
“These positive study results in our pharmacokinetics and safety studies for Probudur continue to demonstrate both immediate relief as well as sustained relief at the wound site,” said Jatinder Dhaliwal, Chief Executive Officer of Virpax Pharmaceuticals. “The completion of these studies brings us another step closer to filing our Investigational New Drug Application (IND) for Probudur.”
Probudur works as a local anesthetic by blocking sodium channels to prevent pain signals from reaching the brain. Preclinical studies have shown its ability to control pain for up to five days in a rat model and a slow release of bupivacaine for as long as six days in laboratory tests.
The drug is being developed to provide safe and effective pain management during the perioperative period while significantly reducing or eliminating the need for opioids after surgery in approved cases. If successful, it could become a valuable tool in combating opioid dependence while improving patient outcomes through reliable, long-lasting pain relief.
With these steps, Virpax continues to advance its mission of developing innovative pain management solutions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.